Cargando…
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
PURPOSE: The aim of this study was to improve the intratumoral accumulation of an antibody–drug conjugate (ADC) and minimize its off-target toxicity, SKB264, a novel anti-trophoblast antigen 2 (TROP2) ADC that was developed using 2-methylsulfonyl pyrimidine as the linker to conjugate its payload (KL...
Autores principales: | Cheng, Yezhe, Yuan, Xiaoxi, Tian, Qiang, Huang, Xiuying, Chen, Yang, Pu, Yuzhi, Long, Hu, Xu, Mingyu, Ji, Yafei, Xie, Jia, Tan, Yuping, Zhao, Xi, Song, Hongmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817100/ https://www.ncbi.nlm.nih.gov/pubmed/36620535 http://dx.doi.org/10.3389/fonc.2022.951589 |
Ejemplares similares
-
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015) -
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020) -
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020) -
Megadalton-node assembly by binding of Skb1 to the membrane anchor Slf1
por: Deng, Lin, et al.
Publicado: (2014) -
Fission yeast Srr1 and Skb1 promote isochromosome formation at the centromere
por: Mongia, Piyusha, et al.
Publicado: (2023)